290 related articles for article (PubMed ID: 21737892)
1. Adjuvant Therapy of Pancreatic Cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Sharma C; Horowitz D; Chabot J; Saif MW
JOP; 2011 Jul; 12(4):343-6. PubMed ID: 21737892
[TBL] [Abstract][Full Text] [Related]
2. Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Brus C; Saif MW
JOP; 2010 Jul; 11(4):321-3. PubMed ID: 20601802
[TBL] [Abstract][Full Text] [Related]
3. Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Li J; Merl MY; Chabot J; Saif MW
JOP; 2010 Jul; 11(4):310-2. PubMed ID: 20601799
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant treatment for ampullary cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Kim R; Chabot J; Saif MW
JOP; 2011 Jul; 12(4):362-3. PubMed ID: 21737897
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Merl MY; Abdelghany O; Li J; Saif MW
JOP; 2010 Jul; 11(4):317-20. PubMed ID: 20601801
[TBL] [Abstract][Full Text] [Related]
6. Updates on first-line treatment of metastatic pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2011 Jul; 12(4):339-42. PubMed ID: 21737891
[TBL] [Abstract][Full Text] [Related]
7. Updates in pancreatic neuroendocrine carcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Alsamarai S; Libutti SK; Saif MW
JOP; 2010 Jul; 11(4):336-40. PubMed ID: 20601807
[TBL] [Abstract][Full Text] [Related]
8. Locally advanced pancreatic adenocarcinoma: are we making progress?. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Li J; Ng J; Allendorf J; Saif MW
JOP; 2011 Jul; 12(4):347-50. PubMed ID: 21737893
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Merika E; Syrigos KN; Saif MW
JOP; 2010 Jul; 11(4):328-30. PubMed ID: 20601804
[TBL] [Abstract][Full Text] [Related]
10. Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Cheng H; Merika E; Syrigos KN; Saif MW
JOP; 2011 Jul; 12(4):334-8. PubMed ID: 21737890
[TBL] [Abstract][Full Text] [Related]
11. Palliative care of pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Saif MW
JOP; 2011 Jul; 12(4):355-7. PubMed ID: 21737895
[TBL] [Abstract][Full Text] [Related]
12. Updates in locally advanced pancreatic cancer. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Chang BW; Siccion E; Saif MW
JOP; 2010 Jul; 11(4):313-6. PubMed ID: 20601800
[TBL] [Abstract][Full Text] [Related]
13. Diabetes and pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Hsu C; Saif MW
JOP; 2011 Jul; 12(4):330-3. PubMed ID: 21737889
[TBL] [Abstract][Full Text] [Related]
14. Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Dimou AT; Syrigos KN; Saif MW
JOP; 2010 Jul; 11(4):324-7. PubMed ID: 20601803
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of pancreatic cancer patients with diabetes mellitus: is diabetes a poor prognostic factor? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Kang SP; Saif MW
JOP; 2010 Jul; 11(4):334-5. PubMed ID: 20601806
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers and pharmacogenetics in pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Xu X; Strimpakos AS; Saif MW
JOP; 2011 Jul; 12(4):325-9. PubMed ID: 21737888
[TBL] [Abstract][Full Text] [Related]
17. Updates on treatment of gemcitabine-refractory pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Makrilia N; Syrigos KN; Saif MW
JOP; 2011 Jul; 12(4):351-4. PubMed ID: 21737894
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant strategies for resectable pancreatic cancer: have we made progress?
Russo S; Jain AK; Saif MW
JOP; 2012 Mar; 13(2):139-42. PubMed ID: 22406585
[TBL] [Abstract][Full Text] [Related]
19. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic cancer and thrombosis. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Shah MM; Saif MW
JOP; 2010 Jul; 11(4):331-3. PubMed ID: 20601805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
